Skip to Main Content

Paper Details

Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
mSystems
6
2023
COVID-, COVID-19, SARS, SARS-, SARS-CoV, SARS-CoV-2, mRNA, nucleic acids, people, severe acute respiratory syndrome coronavirus
COVID-19, COVID-19 Vaccines, Humans, Nucleic Acid-Based Vaccines, Pandemics, SARS-CoV-2, Vaccine Development, Vaccines, Subunit, Viral Vaccines
Author NameAffiliation
Halie M RandoUniversity of Pennsylvania
Halie M RandoUniversity of Colorado School of Medicine
Halie M RandoCenter for Health AI, University of Colorado School of Medicine
Halie M RandoUniversity of Colorado School of Medicine
Ronan LordanUniversity of Pennsylvania
Ronan LordanInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania
Ronan LordanPerelman School of Medicine, University of Pennsylvania
Alexandra J LeeUniversity of Pennsylvania
Alexandra J LeeUniversity of Pennsylvania
Amruta NaikChildren's Hospital of Philadelphia
Nils WellhausenUniversity of Pennsylvania
Elizabeth SellPerelman School of Medicine, University of Pennsylvania
Likhitha KollaPerelman School of Medicine, University of Pennsylvania
Anthony GitterUniversity of Wisconsin-Madison
Anthony GitterMorgridge Institute for Research
Casey S GreeneUniversity of Pennsylvania
Casey S GreeneUniversity of Colorado School of Medicine
Casey S GreeneCenter for Health AI, University of Colorado School of Medicine
Casey S GreeneUniversity of Colorado School of Medicine
Casey S GreeneAlex's Lemonade Stand Foundation
Casey S GreeneUniversity of Pennsylvania
Casey S GreeneUniversity of Colorado School of Medicine
Casey S GreeneCenter for Health AI, University of Colorado School of Medicine
Casey S GreeneUniversity of Colorado School of Medicine
Casey S GreeneAlex's Lemonade Stand Foundation
  • 1 - 25

Datasets